A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in

2018 ◽  
Vol 32 (5) ◽  
pp. 768-775 ◽  
Author(s):  
A. Petridis ◽  
P. Panagakis ◽  
E. Moustou ◽  
T. Vergou ◽  
P. Kallidis ◽  
...  
Author(s):  
B. Dhillon ◽  
P. Aspinall ◽  
T. Aslam ◽  
P. Halpin ◽  
A. Vani ◽  
...  

The principal aim of this research proposal was to develop quality of life and relevant visual function criteria to provide a rational decisional framework to be used as a basis for individual and policy decisions on cataract referral and surgery. There are two key objectives within this overall aim. The first is to identify reliable and effective quality of life and visual function criteria to determine the threshold for surgery for each individual patient in which false positive and false negative errors are minimized. The second is to provide a decisional framework in which risk factors may be incorporated to assess the likely outcome benefits from surgery.


Author(s):  
M Petitclerc ◽  
M Bhogal ◽  
S Dhani ◽  
L Belle Blagrove

Background: Health-related quality of life (HRQoL) data is valuable, but limited. This analysis describes the impact of onabotulinumtoxinA treatment on HRQoL and level of treatment satisfaction in cervical dystonia (CD) patients. Methods: A multicenter, prospective, observational study in CD patients initiating onabotulinumtoxinA treatment (NCT01655862); ≤8 treatments administered at the physician’s discretion. Primary measures (baseline, 4/8 weeks post-treatment, and before final treatment): pain numeric rating scale (PNRS) and cervical dystonia impact profile questionnaire (CDIP-58). Secondary measures (8 weeks post-treatment): patient/physician treatment satisfaction. Results: 61 patients (31.3-86.3 years old) were enrolled (efficacy cohort); majority had moderately severe CD (77.0%) and were female (77%). CDIP-58 domain and PNRS scores decreased from baseline, with significant changes (p<.0001) by 4 weeks post-treatment 3 (mean±SD): symptoms (-18.8±16.1), daily activities (-7.2±13.7), psychosocial sequelae (-17.4±13.4), and PNRS (-1.8±3.3). Most patients (78.0% and 94.4%) felt their condition was improved and majority of physicians (68.9% and 75.0%) indicated satisfaction with patients’ responses following treatments 1 and 2, respectively. 27 patients reported 56 treatment-related adverse events (52 resolved, 4 ongoing); none were serious. Conclusions: No new safety signals were identified. Patients and physicians appear to be satisfied with onabotulinumtoxinA treatment for CD. Results suggest that onabotulinumtoxinA treatment may help improve HRQoL.


Author(s):  
Jolly M. Harkhani ◽  
Ashish Jagati ◽  
Hemant Tiwari ◽  
Shikha V. Sood ◽  
Supriya D. Malhotra

<p class="abstract"><strong>Background: </strong>Contact dermatitis (CD) is a common inflammatory skin condition due to T-cell mediated immune reaction on exposure to different allergens. The disease significantly affects Quality of Life (QoL) and all over impact can be seen in Pharmacoeconomics.</p><p class="abstract"><strong>Methods: </strong>This is the prospective observational study done between October 2019 to February 2020 at Dermatology outpatient department (OPD) of a tertiary care teaching hospital. Patients diagnosed with CD aged eighteen years or older of either gender and willing to give written consent were included in study. The impact of CD on the QoL of affected persons was assessed using the Dermatology Life Quality Index (DLQI). Direct, indirect and total cost as well as percentage variation in cost of individual drugs was calculated for Pharmacoeconomics analysis.</p><p class="abstract"><strong>Results:</strong> The study population consisted of 180 patients. The most commonly prescribed drugs were corticosteroids (47.44%). The average score of DLQI at baseline was 8.97±4.85. The DLQI score was significantly more impaired in women as compared to men (12.91versus 4.93) (p=0.0001). Average income per month was 11,611.11±230.34₹. The average direct, indirect and total cost was 131.55±70.55 ₹, 136.44±16.93 ₹ and 168.11±74.08₹ respectively. The percentage variation of cost was largest for prednisolone 5 mg tablet and least for clobetasol cream (0.05%).</p><p class="abstract"><strong>Conclusions: </strong>The impact of CD on QoL and Pharmacoeconomic burden is significant and requires specific attention in health care facilities.  </p>


Author(s):  
Justyna Dąbrowska-Bień ◽  
Henryk Skarżyński ◽  
Sebastian Filip Górski ◽  
Piotr Henryk Skarżyński

Abstract Introduction Nasal obstruction is a common symptom in otorhinolaryngological practice. It can impact significantly on the quality of life of the individual. Objective The primary goal of the present study was to evaluate quality of life after septoplasty in adults with nasal obstruction. A secondary goal was to assess the effectiveness of septoplasty. Methods This was a single institution prospective observational study. Patients had experienced septal deviation and symptomatic nasal obstruction with no benefit from medical treatment. There were 51 patients who completed the Nasal Obstruction Symptom Evaluation (NOSE-POL) scale as well as theVisual Analogue Scale (VAS) before undergoing septoplasty, 3 months later, and finally 7 months after surgery. Patients evaluated changes in their nasal obstruction and changes in their quality of life using the Clinical Global Impression Scale (CGI-S). Results There was a significant improvement in nasal obstruction after septoplasty. Before septoplasty, the mean score on NOSE was 60.3 ± 20.4; 3 months after surgery, it was 32.9 ± 16.8; and 7 months after surgery it was 39.6 ± 33.2. The VAS results also proved a significant enhancement in nasal obstruction after septoplasty. Patients reported an improvement in nasal obstruction as well as a positive change in quality of life, confirming the effectiveness of septoplasty. Conclusions In patients with deformed septum, septoplasty contributes to high satisfaction of the patient and a compelling improvement in disease-specific quality of life. The NOSE-POL questionnaire is a useful tool for measuring the outcomes of this procedure.


2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
V. Porsdal ◽  
O.K. Kleivenes ◽  
C. Beal ◽  
P. Svanborg

Aims:It is known that psychiatric disorders often lead to unhealthy life styles and reduced quality of life, which can lead to weight gain, possibly enhanced by psychotropic treatment.Solutions for Wellness (SfW) is an educational program for life style changes for psychiatric patients. This observational study evaluated the effectiveness of SfW.Method:30 psychiatric clinics collected data for the study. Quality of life was measured by the Subjective Wellbeing under Neuroleptics scale (SWN), at baseline and at the end of SfW participation at 3 months. Demographic, disease and treatment data were also collected. A control group consisted of patients from centers that did not offer the SfW program.Results:314 patients were enrolled in SfW group, 59 in the control group. 54% of the total group had schizophrenia, 67% received atypical antipsychotics. The baseline mean BMI in the SfW group was 31.7 kg/m2.SWN scores for the SfW group improved significantly from baseline to the end of the program (mean increase 3.3 ± 12.2), but not significantly more than for the control group (mean difference 1.4, p = 0.4158 (t-test)). The SfW group demonstrated a significant decrease in BMI, weight and waist circumference from baseline. The decreases were significantly larger compared to the control group for BMI (p = 0.0018) and weight (p = 0.0027) (t-tests).Conclusion:Patients in the SfW program improved in BMI, weight, waist circumference and SWN total score. Changes in weight and BMI were significantly larger in the SfW group compared to the control group.


Sign in / Sign up

Export Citation Format

Share Document